Table 2.
Demographic, procedural, and sedation data of low-risk and high-risk groups
| Variable | High risk (n=218) | Low risk (n=396) | P-value |
|---|---|---|---|
| Demographic data | |||
| Mean age ± SD, years | 51.5 ± 10.8 | 49.0 ± 11.9 | 0.011 |
| Sex, male, n (%) | 164 (75.2) | 183 (46.2) | <0.001 |
| Mean height ± SD (cm) | 165.9 ± 7.5 | 162.5 ± 8.8 | <0.001 |
| Mean weight ± SD (kg) | 73.6 ± 10.6 | 60.0 ± 10.0 | <0.001 |
| Mean BMI ± SD (kg/m2) | 26.7 ± 2.8 | 22.6 ± 2.7 | <0.001 |
| HTN, n (%) | 92 (42.2) | 45 (11.4) | <0.001 |
| DM, n (%) | 24 (11.0) | 16 (4.0) | 0.001 |
| ASA class | <0.001 | ||
| I, n (%) | 103 (47.2) | 315 (79.5) | |
| II, n (%) | 115 (52.8) | 81 (20.5) | |
| Mallampati score | <0.001 | ||
| I, n (%) | 64 (29.4) | 201 (50.8) | |
| II, n (%) | 119 (54.6) | 185 (46.7) | |
| III, n (%) | 35 (16.0) | 10 (2.5) | |
| Procedure data | |||
| Mean EGD time ± SD, min | 5.2 ± 1.3 | 5.3 ± 1.5 | 0.623 |
| Mean colonoscopy time ± SD, min | 13.6 ± 4.2 | 13.6 ± 4.3 | 0.989 |
| Total endoscopy time ± SD, min | 18.4 ± 4.3 | 19.1 ± 4.8 | 0.065 |
| Sedation data | |||
| Mean TCI propofol concentration at the initial of EGD ± SD, µg/mL | 3.0 ± 0.2 | 3.0 ± 0.3 | 0.176 |
| Mean TCI propofol concentration at the end of EGD ± SD, µg/mL | 3.0 ± 0.5 | 3.2 ± 0.5 | <0.001 |
| Mean TCI propofol concentration during colonoscopy ± SD, µg/mL | 2.5 ± 0.3 | 2.6 ± 0.4 | <0.001 |
| Mean total propofol dose for EGD ± SD, mg | 116.9 ± 24.3 | 99.5 ± 26.6 | <0.001 |
| Mean total propofol dose during colonoscopy ± SD, mg | 48.2 ± 22.5 | 51.6 ± 30.0 | 0.109 |
| Mean total propofol dose ± SD, mg | 181.6 ± 35.4 | 164.4 ± 43.3 | 0.009 |
| End-tidal CO2 during colonoscopy ± SD, mmHg | 43.2 ± 6.4 | 41.1 ± 6.4 | <0.001 |
Abbreviations: SD, standard deviation; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; ASA, American Society for Anesthesiology; EGD, esophagogastroduodenoscopy; TCI, target-controlled infusion.